Celularity Inc. (NASDAQ:CELU – Get Free Report)’s share price was down 8.8% during trading on Wednesday . The company traded as low as $2.65 and last traded at $2.68. Approximately 25,540 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 104,829 shares. The stock had previously closed at $2.94.
Celularity Price Performance
The business’s 50 day moving average is $2.92 and its 200 day moving average is $3.34.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Celularity stock. Keynote Financial Services LLC bought a new stake in shares of Celularity Inc. (NASDAQ:CELU – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,566 shares of the company’s stock, valued at approximately $81,000. Keynote Financial Services LLC owned approximately 0.08% of Celularity at the end of the most recent reporting period. 19.02% of the stock is owned by institutional investors and hedge funds.
Celularity Company Profile
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
See Also
- Five stocks we like better than Celularity
- Pros And Cons Of Monthly Dividend Stocks
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- How to Calculate Return on Investment (ROI)
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- How to Most Effectively Use the MarketBeat Earnings Screener
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.